Salute e Benessere

Virbac : Declaration of the number of shares and voting rights 07/2024

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsJuly, 31 20248 458 000Gross total of voting rights :...
Nasdaq GlobeNewswire
10/09/2024

World Stroke Organization and Philips call for action to expand access to…

September 10, 2024 Joint policy paper provides recommendations for effective policymaking and investments in stroke centerswith specialized treatments to improve health outcomes and reduce costsTimely access to mechanical thrombectomy – a proven minimally invasive therapy to remove the blood clot that caused the stroke – has the potential to revolutionize treatment for major ischemic strokes, but the procedure remains the exception rather than the norm Amsterdam, the Netherlands...
Nasdaq GlobeNewswire
10/09/2024

Cognoa Appoints Michael Butler as Board Executive Chair to Further Propel Access…

With more than three decades of experience in healthcare delivery, Mike Butler is renowned for his transformative leadership at Providence, one of the largest health systems in the US, where he served as President from 1998 until his retirement in 2020. Under his leadership, Providence's annual revenue increased from $2 billion to $25 billion, and Butler was instrumental in devising a unified growth strategy that expanded Providence's network of care throughout the western United States. His…
PR Newswire
10/09/2024

PharmaForceIQ Announces Majority Investment by Eir Partners to Support and…

John Blakeley, Chairman, PharmaForceIQ commented: John Blakeley, Chairman, PharmaForceIQ commented: "We will continue to invest in PFIQ's people, technology and customer experience. As we reach this inflection point, the support and capital from a proven investor like Eir is expected to fuel further growth allowing PFIQ to better serve clients through its strategic omnichannel platform." Hemal Somaiya, Head of Omnichannel, PharmaForceIQ added: "Engaging and informing health…
PR Newswire
10/09/2024

A new report from the Access to Medicine Foundation reveals how patient-focused…

Ahead of the 2024 Access to Medicine Index, the Foundation examined the patient reach commitments and measurement approaches of the 20 companies that will be ranked in the upcoming Index in November. The analysis identified 42 unique approaches to measuring patient reach, each with varying degrees of comprehensiveness. Companies like AstraZeneca, Novartis, and Roche are leading the way with more nuanced approaches that go beyond simply tracking sales, enhancing the accuracy of their patient...
Nasdaq GlobeNewswire
10/09/2024

Vaping Expected to Increase COPD Health and Economic Burden by 2050

New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates. 88.7 million new COPD hospitalizations projected across Western Europe between 2019 - 2050Vaping projected to incur almost €30 billion additional direct and indirect costs by 2050 €4.9 trillion projected cumulative...
Nasdaq GlobeNewswire
10/09/2024

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin…

2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, visual disturbances or hepatotoxicity as of the data cutoff date1 PK profile supports once-daily dosing Company plans to rapidly initiate Phase 2 studies of ORX750 in patients with...
Nasdaq GlobeNewswire
10/09/2024

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Sept.10, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an...
Nasdaq GlobeNewswire
10/09/2024

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per September 6, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,289,066 shares, corresponding to 4.97% (previously 5.00%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
10/09/2024

Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in…

® is now available for patients with prostate cancer. PYLCLARI® (INN: Piflufolastat ( 18 F) also known as ( 18 F)-DCFPyL) is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a...
Nasdaq GlobeNewswire
10/09/2024

RingConn Showcases Gen 2 Smart Ring at IFA 2024: Revolutionizing Sleep…

Innovative Sleep Apnea Monitoring Innovative Sleep Apnea Monitoring The RingConn Gen 2 distinguishes itself as the first smart ring to provide Sleep Apnea monitoring. Unlike traditional monitoring methods, the Gen 2 offers a more convenient, comfortable, and cost-effective way to assist users in understanding their sleep conditions. With three continuous hours of real-time sleep monitoring overnight, users can gain insights into potential Sleep Apnea symptoms and their overall sleep health...
PR Newswire
10/09/2024

IonOpticks partners with Adelis to accelerate global expansion and innovation

The strategic partnership will enable IonOpticks to scale its operations globally, enhancing product development and better positioning the company to serve its growing customer base. Being closer to its customers and collaborators while also ensuring compatibility across major LC-MS platforms is a key priority, allowing researchers worldwide to benefit from IonOpticks' class-leading chromatography. Adelis' extensive experience, industrial advisor network and resources will support IonOpticks in…
PR Newswire
10/09/2024

ONWARD® Medical Reports Half Year 2024 Results and Provides a Business Update

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Up-LIFT Study results published in Nature Medicine De Novo application submitted to FDA to obtain clearance to market the investigational ARC-EX ®System in the United StatesUp to EUR 52.5M in growth financing obtained from US-based Runway Growth CapitalSeveral additional milestones achieved with the investigational ARC-BCI ™System,...
Nasdaq GlobeNewswire
10/09/2024

XRP Healthcare Enters the Limitless World of AI

The chatbot is the first major development from XRP Healthcare's in-house AI team, reflecting the company's deep commitment to harnessing AI to enhance healthcare services. This move comes as XRP Healthcare sets its sights on expanding across Uganda and Africa-wide, acquiring key healthcare businesses such as pharmacies, medical centres, and hospitals. With the successful registration of its Ugandan trademark, the establishment of bank accounts, legal frameworks, and the securing of work…
PR Newswire
10/09/2024

XRP Healthcare Enters the Limitless World of AI

The chatbot is the first major development from XRP Healthcare's in-house AI team, reflecting the company's deep commitment to harnessing AI to enhance healthcare services. This move comes as XRP Healthcare sets its sights on expanding across Uganda and Africa-wide, acquiring key healthcare businesses such as pharmacies, medical centres, and hospitals. With the successful registration of its Ugandan trademark, the establishment of bank accounts, legal frameworks, and the securing of work…
PR Newswire
10/09/2024

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration…

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® inSecond-Line Non-Small Cell Lung CancerTrial begins in the United States, Canada, Europe and United Kingdom after successful regulatory authorizations in 14 countries.Trial in Progress presentation at the 2024World Conference on Lung Cancerin San Diego and at theEuropean Society for Medical Oncologycongress 2024 in Barcelona. Nantes, France –...
Nasdaq GlobeNewswire
10/09/2024

Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for…

Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in 20 markets in Central and Eastern Europe. Santhera Pharmaceuticals and GENESIS Pharma have signed a distribution agreement for 20 markets in Central and Eastern Europe. This strategic collaboration aims to address unmet medical needs by allowing...
Nasdaq GlobeNewswire
10/09/2024

Global Pharmaceutical Excipients Market to Register Growth at a CAGR of ~6% by…

Key Takeaways from the Pharmaceutical Excipients Market Report Key Takeaways from the Pharmaceutical Excipients Market Report To read more about the latest highlights related to the pharmaceutical excipients market, get a snapshot of the key highlights entailed in the Global Pharmaceutical Excipients Market Report Pharmaceutical Excipients Overview Pharmaceutical excipients are non-active ingredients used in drug formulations to aid the production, stability, and effectiveness...
PR Newswire
09/09/2024

Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034…

Although the cause of IPF is unknown, researchers postulate that the disease probably results from genetic and environmental factors. There is a strong possibility that genetic changes increase a person's risk of developing IPF and subsequent exposure to certain environmental factors that further trigger the disease. However, much is still unknown about this emerging field of study. Although the cause of IPF is unknown, researchers postulate that the disease probably results from genetic and...
PR Newswire
09/09/2024

PATH Appoints Dr Bilal Mateen as Inaugural Chief AI Officer

Dr. Mateen is a physician by training with an academic background in health-related applications of data science and machine learning. Prior to joining PATH, he served as the Clinical Technology Lead and Senior Manager for Digital Technology at the Wellcome Trust, one of the world's largest philanthropic foundations supporting science and health research. Dr. Mateen is a physician by training with an academic background in health-related applications of data science and machine learning...
PR Newswire
09/09/2024

Microfluidic Chips Market Size to Grow USD 8770.5 Million by 2030 with a CAGR of…

Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-12L12225/Global_Microfluidic_Chips_Market Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-12L12225/Global_Microfluidic_Chips_Market Major Factors Driving the Growth of Microfluidic Chips Market: Due to the growing importance of microfluidic chips in a variety of applications, including drug research, environmental monitoring, and medical diagnostics, the market for these chips is...
PR Newswire
09/09/2024

Boehringer's zongertinib shows encouraging efficacy and tolerability profile in…

Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR) 1Preliminary activity in patients with brain metastases were also observed, with an intracranial response of 33% and 74% disease control rate (DCR) Zongertinib was generally well tolerated, with mostly mild and manageable treatment related adverse events (TRAE) and low discontinuation rate due to toxicity (3%)...
Nasdaq GlobeNewswire
09/09/2024

Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for…

The assay meets the preferred target product profiles (TPPs) issued by the WHO, which guide manufacturers, suppliers, and researchers developing new assays for detection of viruses causing mpox. Additionally, it aligns with the preferred target analyte criteria for distinguishing between Clade I and II. The assay meets the preferred target product profiles (TPPs) issued by the WHO, which guide manufacturers, suppliers, and researchers developing new assays for detection of viruses causing…
PR Newswire
09/09/2024

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple…

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutidePlacebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly dosesDapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based...
Nasdaq GlobeNewswire
09/09/2024
Altri  Comunicati